Want to see RVMD full AI Analyst Report?
RVMD Stock Chart & Stats
$189.23
$0.48(0.25%)
At close: 4:00 PM EDT
$189.23
$0.48(0.25%)
Day’s Range― - ―
52-Week Range$34.00 - $194.56
Previous CloseN/A
Volume1.29M
Average Volume (3M)2.70M
Market Cap
$39.87B
Enterprise Value$17.79K
Total Cash (Recent Filing)$1.91B
Total Debt (Recent Filing)$437.27M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Aug 05, 2026EPS Estimate
-2.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.11
Shares Outstanding212,596,470
10 Day Avg. Volume1,922,310
30 Day Avg. Volume2,704,654
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)9.28
Price to Sales (P/S)0.00
P/FCF Ratio-16.57
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$201.12Price Target Upside6.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)-7.91
Revenue Forecast (FY)$99.19M
Bulls Say, Bears Say
Bulls Say
Practice‑changing Phase III EfficacyA randomized Phase III showing a 60% mortality reduction and median OS >1 year materially de‑risks daraxonrasib's core program. This transforms competitive positioning in KRAS‑driven cancers, supports regulatory filings and durable commercial potential across multiple indications, and strengthens long‑term franchise value.
Strong Pro Forma Cash RunwayA roughly $4.0B pro forma cash balance provides multi‑year runway to complete registrational trials, scale manufacturing and build commercial infrastructure without immediate reliance on dilutive financings. This financial flexibility lets management execute strategy and absorb development timing variability.
Diversified Registrational PipelineA broad set of registrational programs across indications and combinations spreads clinical risk and increases probability of at least one approvable asset. Expanding enrollment and multiple assets in development create multiple clinical and regulatory value paths, supporting sustainable long‑term growth potential.
Bears Say
Heavy, Worsening Cash BurnSustained ~>$1B annual negative operating and free cash flow creates ongoing funding needs despite the large pro forma balance. Continued high burn narrows optionality, forces prioritization of programs, and raises the risk that future unexpected costs or slower trial progress necessitate additional financing or program cuts.
Zero Revenue And Expanding LossesAs a clinical‑stage biotech with no product revenue, the company remains wholly dependent on collaborations and capital markets. Rapidly widening losses erode equity cushions over time, increase reliance on external funding, and amplify dilution risk if trial timelines slip or anticipated milestones are delayed.
Rising Operating Expenses And Stock‑based CompMaterial increases in stock‑based compensation and GAAP operating expense guidance permanently raise reported cost bases and could pressure future margins. Elevated equity compensation dilutes shareholders and signals higher fixed compensation expense that may be hard to reverse while scaling commercial and R&D efforts.
Revolution Medicines News
RVMD FAQ
What was Revolution Medicines, Inc.’s price range in the past 12 months?
Revolution Medicines, Inc. lowest stock price was $34.00 and its highest was $194.56 in the past 12 months.
What is Revolution Medicines, Inc.’s market cap?
Revolution Medicines, Inc.’s market cap is $39.87B.
When is Revolution Medicines, Inc.’s upcoming earnings report date?
Revolution Medicines, Inc.’s upcoming earnings report date is Aug 05, 2026 which is tomorrow.
How were Revolution Medicines, Inc.’s earnings last quarter?
Revolution Medicines, Inc. released its earnings results on May 06, 2026. The company reported -$2.29 earnings per share for the quarter, missing the consensus estimate of -$1.836 by -$0.454.
Is Revolution Medicines, Inc. overvalued?
According to Wall Street analysts Revolution Medicines, Inc.’s price is currently Undervalued.
Does Revolution Medicines, Inc. pay dividends?
Revolution Medicines, Inc. does not currently pay dividends.
What is Revolution Medicines, Inc.’s EPS estimate?
Revolution Medicines, Inc.’s EPS estimate is -2.04.
How many shares outstanding does Revolution Medicines, Inc. have?
Revolution Medicines, Inc. has 212,596,470 shares outstanding.
What happened to Revolution Medicines, Inc.’s price movement after its last earnings report?
Revolution Medicines, Inc. reported an EPS of -$2.29 in its last earnings report, missing expectations of -$1.836. Following the earnings report the stock price went down -5.666%.
Which hedge fund is a major shareholder of Revolution Medicines, Inc.?
Currently, no hedge funds are holding shares in RVMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Revolution Medicines Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$201.12 (6.29% Upside)
$201.12 (6.29% Upside)
Blogger Sentiment
Bullish
RVMD Sentiment 71%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 808.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
408.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.72%
Trailing 12-Months
Company Description
Revolution Medicines, Inc.
Revolution Medicines, Inc. (RVMD) is a clinical-stage biotechnology company focused on discovering and developing targeted therapies for cancer, with an emphasis on RAS and related signaling pathways. The company’s core activities center on researching, developing, and clinically testing small-molecule oncology drugs (including RAS(ON) inhibitors) intended to address genetically defined tumors driven by mutations such as KRAS. As a clinical-stage company, its primary “products” are investigational drug candidates progressing through clinical trials rather than marketed, approved therapeutics.
RVMD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed overwhelmingly positive clinical and strategic progress—most notably the practice‑changing RASolute 302 Phase III result (60% reduction in risk of death) and a large capital raise that materially strengthens the balance sheet—while candidly disclosing near‑term financial impacts from rapid program acceleration, elevated stock‑based compensation and higher operating expenses. Operational and regulatory timing uncertainties and trial design complexities were noted, but the program momentum, supportive data across multiple assets, and strong funding availability suggest the positives materially outweigh the headwinds.View all RVMD earnings summariesRVMD Stock 12 Month Forecast
Average Price Target
$201.12
▲(6.29% Upside)
Technical Analysis
Ownership Overview
2.11% Insiders
18.40% Mutual Funds
1.11% Other Institutional Investors
63.18% Public Companies and Individual Investors